5.085

6.01% -0.325

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $5.085, with a volume of 1.22M. It is down -6.01% in the last 24 hours and down -11.10% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$5.41

Open:

$5.41

24h Volume:

1.22M

Relative Volume:

1.01

Market Cap:

$850.47M

Revenue:

$62.04M

Net Income/Loss:

$-533.34M

P/E Ratio:

-1.2972

EPS:

-3.92

Net Cash Flow:

$-473.07M

1W Performance:

-17.45%

1M Performance:

-11.10%

6M Performance:

-47.03%

1Y Performance:

-46.81%

1-Day Range:

$5.08

$5.45

1-Week Range:

$5.04

$6.29

52-Week Range:

$4.95

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

408

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	5.085	850.47M	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

10:28 AM

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

10:28 AM

10:15 AM

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

10:15 AM

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025

May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025